saxenda or semaglutide GLP-1 analogs, new trend in obesity treatment, become even more effective < Pharma < Article Wegovy vs. Saxenda: A Comparison

95% CI, 1.45 to 2.62

Those treated with Wegovy, whose active ingredient is semaglutide, experienced a reduction in major cardiac events by up to 28%, and saw a 24% reduction in the risk of cardiac-related death and a 19% reduction in the risk of death from any cause

Transport of insulin across the blood-brain barrier: saturability at euglycemic doses of insulin

preserves NAD+ salvage and SAM availability Regulatory status: not approved by the FDA or any other regulatory authority

Some people experience noticeable drowsiness while taking Mounjaro, and you should speak with your healthcare provider about persistent or severe sleepiness